Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 2/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.34 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.34 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26693373 | 0.93 | HRH3 (0.34) | HRH3GNAI3GNAO1GNAI1USP2 | |
| SCHEMBL21421592 | 0.89 | SMN1; SMN2 (0.37) | GBA1ALDH1A1 | |
| SCHEMBL21421584 | 0.87 | SMN1; SMN2 (0.36) | ALDH1A1 | |
| SCHEMBL22520687 | 0.85 | ALDH1A1 (0.46) | HRH3GNAI3GNAO1GNAI1USP2 | |
| SCHEMBL29325698 | 0.85 | ALDH1A1 (0.46) | HRH3GNAI3GNAO1GNAI1USP2 | |
| SCHEMBL20230942 | 0.84 | GNAI3 (0.47) | GNAI3GNAO1GNAI1 | |
| SCHEMBL22297421 | 0.84 | GBA1 (0.36) | GBA1HRH3GNAI3GNAO1GNAI1 | |
| SCHEMBL22520691 | 0.84 | KDM4E (0.40) | HRH3GNAI3GNAO1GNAI1ALDH1A1 | |
| SCHEMBL22851654 | 0.84 | GNAI3 (0.47) | GNAI3GNAO1GNAI1 | |
| SCHEMBL12228112 | 0.83 | ALDH1A1 (0.47) | HRH3USP2ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11802132-B2 | Small molecules for inducing selective protein degradation and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11802132-B2 | Small molecules for inducing selective protein degradation and uses thereof | BAZ2A, BRD3, BRPF3 | GBA1 3783/4885HRH3 331/4885GNAI3 618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.